Medtronic

Evolut™ TAVR platform

Patient GREEN, IAN Male

Height Weight

Physician Dr. Ravinay Bhindi m Hospital Royal North Shore kg Hospital

Received Date 29-May-2025 Reviewed Date 30-May-2025

Year Of Birth (Age) 1946 (78)

BMI

EOA needed to achieve an $iEOA > 0.85 \text{ cm}^2/\text{m}^2$


City Sydney Country Australia

Clinical History

Case #: 31540520


Anticipated Implant Date: Not Provided

MEDTRONIC ANALYSIS



LVOT

Diameter (mm)	27.0	x 32.0 ,	29.5
Perimeter (mm)	Min 93.3	Max , Derived Ø (mm)	Mean 29.7
Area (mm²)	673.2	, Derived Ø (mm)	29.3



Max Ascending Aorta Diameter (mm) Sinotubular Junction

Sinus of Valsalva Diameter (mm) Sinus of Valsalva Height (mm)

Diameter (mm)

Coronary Ostia Height (mm)

42.3


40.7 40.9 Max

45.9 41.1 45.3 LCC RCC NCC 36.6 32.3 34.8 LCC RCC NCC

21.1 23.6 Left Right


VIEWS


RAO: 23°, Caudal: 19° Cusp Overlap View 3 Cusp Coplanar View Near Cusp Overlap View






Calcium: Mild ☐ Moderate ☐ Severe ☐







Valve to Coronary Distance (mm)		
	To LCA	To RCA
Valve to STJ Distance (mm)		
	LCC	RCC

VIV ADDITIONAL MEASUREMENTS

Procedural Considerations


Chest and full body CT contains significant double image artifact and blurring - Difficult to determine anatomical and luminal borders - Please consider measurements very gross estimates


Site reports patient has a 25 mm Edwards Perimount 2800 surgical aortic valve (SAV) - Patient appears to have a radiopaque suture device near the SAV - Recommend obtaining Op report for specific SAV information


Possible LAA closure device - please verify with site Dilated ascending aorta Bend seen in descending thoracic aorta


Bend seen in REI, LCI, and LEI Possible bulging seen in LCI Artifact seen in LFA due to hip hardware

Aorta












Aorta







SINUS HEIGHT














Cusp overlap view




Femoral Access - Right





Femoral Access - Left




- Bend seen in LCI and LEI
- Artifact seen in LFA due to hip hardware










Possible bulging seen in LCI


Additional Femoral Images





Possible bulging seen in LCI







Additional Images


Perimount RSR 2800 Valve,8 Magna 3000 Valve9




Site reports patient has a 25 mm Edwards Perimount 2800 surgical aortic valve (SAV) - Patient appears to have a radiopaque suture device near the SAV - Recommend obtaining Op report for specific SAV information











LCA appears to originate above SAV stent posts

RCA appears to originate above SAV stent posts




LCC - VTSTJ not provided as the top of LCC is > 2 mm from the top of SAV stent



Perpendicular Plane

RCC - VTSTJ not provided as the top of RCC is > 2 mm from the top of SAV stent




LCC and RCC - VTA not provided as LCA and RCA originates above SAV stent posts



Possible LAA closure device - please verify with site



Possible LAA closure device - please verify with site



- Dilated ascending aorta
- Bend seen in descending thoracic aorta

Medtronic

Evolut[™] FX TAVI System

Patient valve selection criteria

Evolut FX bioprosthesis valve size selection









Oversizing Percentage

Size Annulus diameter (A) Annulus perimeter‡ Sinus of Valsalva diameter (mean) (B) 44.1 mm ≥ 25 mm Sinus of Valsalva height (mean) (C)

23 mm 23.0 mm 18-20 mm 72.3 mm 56.5-62.8 mm $34.5 \text{ mm} \geq 15 \text{ mm}$ 0%

26 mm 20-23 mm 62.8-72.3 mm ≥ 27 mm ≥ 15 mm 13%

29 mm 23-26 mm 72.3-81.7 mm ≥ 29 mm ≥ 15 mm 26%

34 mm 26-30 mm 81.7-94.2 mm ≥ 31 mm ≥ 16 mm 48%

 ‡ Annulus perimeter = annulus diameter x π .

Selection criteria

Access consideration by MSCT

Minimum transarterial access vessel diameter

Aortic root angulation, femoral access Aortic root angulation, left subclavian Aortic root angulation, right subclavian Vascular access location, direct aortic access

IFU guidance by MSCT

Evolut FX 23/26/29 mm TAVs ≥ 5.0 mm Evolut FX 34 mm TAV ≥ 6.0 mm

Not recommended if > 70 degrees. Not recommended if > 70 degrees.§ Not recommended if > 30 degrees.§

Ascending aorta access site \geq 60 mm from basal plane.^{Ω}

 $^{\$}$ Patients with a patent LIMA or RIMA graft must present with access vessel diameters that are either ≥ 5.5 mm when using model D-EVOLUTFX-2329 or \geq 6.5 mm when using model D-EVOLUTFX-34.

^oFor direct aortic access, ensure access site and trajectory are free of patent RIMA or preexisting patent RIMA graft.

Note the position of any SVGs (A) Annulus diameter (B) Sinus of Valsalva diameter (C) Sinus of Valsalva height (D) Frame height (≈ 45 mm, not including paddles) Illustration not to scale.

CAUTION: For distribution only in markets where CoreValve™ Evolut™ R, CoreValve™ Evolut™ PRO, Evolut™ PRO+, Evolut™ FX Systems and Evolut™ FX+ Systems are approved. See the CoreValve™ Evolut™ R, the CoreValve™ Evolut™ PRO, the Evolut™ PRO+, the Evolut™ FX and the Evolut™ FX+ device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu. For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, the commercial name of the Evolut™ PRO device is Medtronic CoreValve™ Evolut™ PRO System, the commercial name of the Evolut™ PRO+ device is Medtronic CoreValve™ Evolut™ PRO+ System, the commercial name of the Evolut™ FX device is Medtronic Evolut™ FX System and the commercial name of the Evolut™ FX+ device is Medtronic Evolut™ FX+ System.

CAUTION: This report is provided based on information and images provided by the physician to Medtronic. This report is intended to be a resource to support physicians in their determination of proper case selection, device sizing and procedure planning, and is in no way intended to constitute medical advice or in any way replace the independent medical judgment of a trained and licensed physician with respect to any patient needs or circumstances. Physicians must conduct their own measurements and make their own medical judgments based on all of their patient's clinical and diagnostic records and images. Physician is solely responsible for all decisions and any medical judgments relating to patient diagnosis and treatment, including case selection and sizing of the device. Please see the complete Instructions of Use for all product indications, contraindications, precautions, warnings, and adverse events.

See the CoreValve^{\odot} Evolut^{\odot} R, the CoreValve^{\odot} Evolut^{\odot} PRO, the Evolut^{\odot} PRO+ device and the Evolut^{\odot} FX device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

The commercial name of the Evolut^{\mathbb{M}} R device is Medtronic CoreValve^{\mathbb{M}} Evolut^{\mathbb{M}} R System, the commercial name of the Evolut^{\mathbb{M}} PRO System, the commercial name of the Evolut^{\mathbb{M}} PRO+ System, and the commercial name of the Evolut^{\mathbb{M}} FX device is Medtronic Evolut^{\mathbb{M}} FX System.

С€ 0344

Medtronic

Europe

Medtronic International Trading Sàrl. Route du Molliau 31 Case postale CH-1131 Tolochenaz www.medtronic.eu

UC202202685a-evolut-fx-patient-evaluation-criteria-en-we-8664725 @2023 Medtronic. All rights reserved.

Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic.

**Third-party brands are trademarks of their respective owners.

All other brands are trademarks of a Medtronic company.

medtronic.eu

Patient: GREEN, IAN Page 15 of 16 3mensio Structural Heart 10.7

Notes:

Conclusion:

Reviewer Name: #36

Review Date: 30-May-2025